Recent Approaches to Lowering Lp(a): What the Studies Show Approaches that result in lowering of both Lp(a) and LDL Lipoprotein Apheresis (LA): Moriarty and colleagues reported that lipoprotein apheresis (LA) therapy can effectively reduce both LDL and Lp(a), with a significant reduction in future CVD events (94% reduction in major adverse cardiovascular events over a mean treatment period of 48 months).33 In the Pro(a)LiFe-Study (Lipoprotein Apheresis for Lipoprotein(a)- Associated Cardiovascular Disease: Prospective 5 Years of Follow-Up and Apolipoprotein(a) Characterization)34, it was shown that LA has a lasting effect on prevention of cardiovascular events in patients with Lp(a)- hyperlipidemia. Mean Lp(a) concentration was reduced in a single LA treatment by 68.1% on average and a significant decline of the mean annual cardiovascular event rate was observed from 0.58±0.53 2 years before regular LA to 0.11±0.15 thereafter. PCSK9 inhibitors reduce LDL-C by 43% to 64% and lower Lp(a) by 20% to 30%. Analysis of the ODYSSEY OUTCOMES and FOURIER outcomes trials showed enhanced benefit from PCSK9 inhibitor therapy in patients with elevated Lp(a) despite more modest (16-22%) Lp(a) percent lowering in this group.12 Inclisiran, a small interfering RNA molecule that targets PCSK9 messenger RNA, has been evaluated in people with high risk for CVD and elevated LDL-C. Compared with placebo, inclisiran reduced Lp(a) by 25.6% in the ORION-10 trial evaluating inclisiran in patients with ASCVD and by 18.6% in the ORION-11 trial that enrolled subjects with an ASCVD equivalent.35 12
RkJQdWJsaXNoZXIy MjI2NjI=